Company Filing History:
Years Active: 2017
Title: The Innovations of Hans-Henning Ludwig
Introduction
Hans-Henning Ludwig is an accomplished inventor based in Halle/Saale, Germany. His significant contributions to the field of biotechnology are exemplified by his inventive work on peptides that interact with amyloid-beta-peptides. With a keen understanding of molecular biology, Ludwig has developed innovations that could potentially aid in the treatment of neurodegenerative diseases.
Latest Patents
Ludwig holds a patent titled "Peptides that bind to amino-truncated amyloid-beta-peptide and use of said peptides." This patent focuses on peptides that specifically bind to the amino-terminal truncated pEAβ3-42, which features a free glutamic acid residue in positions 3 or 11 in the form of cyclized pyroglutamate. Through the utilization of mirror image phage display technology, four oligopeptides have been identified, showcasing his research's innovative potential.
Career Highlights
Ludwig's professional journey is marked by his role at Forschungszentrum Jülich GmbH, a research center that spearheads advanced technological and scientific research. His contributions have positioned him as a critical player in the ongoing research into amyloid-beta peptides.
Collaborations
Ludwig has collaborated with notable coworkers, including Dieter Willbold and Susanne Aileen Funke. These partnerships have enhanced the depth of his research and innovation, showcasing a collaborative spirit in the scientific community.
Conclusion
Hans-Henning Ludwig's work exemplifies the synergy of creativity and scientific inquiry, resulting in innovations that could have far-reaching implications in medical science. As the field of biotechnology continues to evolve, his contributions stand as a testament to the importance of groundbreaking research in addressing complex health challenges.